Residual Variants May Predict Relapse, Death in AML
Residual variants are associated with a higher risk of relapse and death among AML patients undergoing HSCT in first remission, a study suggests.
Residual variants are associated with a higher risk of relapse and death among AML patients undergoing HSCT in first remission, a study suggests.
Iomab-B plus RIC enables ASCT in a population of AML patients who are not typically eligible for transplant, a phase 3 study suggests.
Living along the Texas-Mexico border is associated with worse survival in children diagnosed with acute lymphoblastic leukemia.
Patients with abnormal chest CTs had worse overall survival, nonrelapse mortality, and pulmonary-related death after allo-HSCT.
Comorbidity burden is an independent predictor of survival in older patients with acute promyelocytic leukemia.
A distinct mutational landscape and worse outcomes were seen for patients with MDS/AML vs those with MDS.
AML research presented at ASH 2022 highlighted promising combination regimens and suggested that some patients may benefit from less intensive treatment.
Prior to the introduction of CAR T-cell therapy, pediatric patients with ALL had limited treatment options for relapsed or refractory disease.
Patients and caregivers scored higher on AML knowledge and perceived greater efficacy in communicating with oncologists.
Rezlidhia (olutasidenib) is now available for the treatment of adults with relapsed or refractory acute myeloid leukemia and a susceptible IDH1 mutation.